A Phase 2 interventional study of vibro-tactile stimulation (VTS) in Adductor Spasmodic Dysphonia, Abductor Spastic Dysphonia and Laryngeal Dystonia, sponsored by University of Minnesota. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by University of Minnesota · Phase 2, Interventional, and Treatment
Among 71 studies in Dysphonia with a site in United States — 20 open to participants now, 21 under way, 1 of them phase 3. Dysphonia · United States.
Among the 71 studies in Dysphonia with a site in United States, this one is the 52nd largest by enrollment of the 53 interventional ones, is one of 6 that started in 2026, is one of 4 in phase 2, and was the 54th registered.
132 studies on the registry are indexed under Dysphonia; 38 are open to participants now.
Browse Dysphonia studies →20 of the 71 studies in Dysphonia with a site in United States are open now, in 1 country. Each count lists the studies.
Of the 25 Dysphonia studies recruiting now, 8 (32%) set no upper age limit and 9 (36%) stop at 75 or younger; 7 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →71 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 6 started in 2026.
Median enrollment 32 across the 53 interventional studies, 170 across the 18 observational. Of the 41 that completed or were terminated, 17 (41%) have results posted.
2 of 71 have an industry lead sponsor. The 10 most frequent:
University of Minnesota is the lead sponsor of 1,216 studies on the registry; 197 are open to participants now.
Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.
University of Minnesota has 6 studies filed under Dysphonia — fewer than ten, so there is no comparison to draw.
12 of the studies in Dysphonia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07145086Phase 3Texas Christian UniversityTranslaryngeal Vibration for Hyperfunctional Voice Disorders | 2027-04-30 |
| NCT06830174Yale UniversitytDCS for Laryngeal Dystonia | 2026-12 |
| NCT03702322University of ArizonaImproving Voice Production for Adults With Age-related Dysphonia | 2026-12-30 |
| NCT05095740MGH Institute of Health ProfessionsEffects of Neuromodulation in Laryngeal Dystonia | 2026-12-31 |
| NCT07443891University of MinnesotaBrain Network Changes After Vibro-tactile Stimulation in Laryngeal Dystonia | 2027-02-28 |
Among the 71 studies in Dysphonia with a site in United States, from their registry updates:
The general aim of the research is to provide scientific evidence that vibro-tactile stimulation (VTS) represents a non-invasive form of neuromodulation that can induce measurable improvements in the speech of patients with laryngeal dystonia (LD) - also called spasmodic dysphonia (SD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low dose refers to receiving VTS 5 times/week for 20 minutes each; non-task-specific, constant stimulation during non-speech
Device: vibro-tactile stimulation (VTS)
Low dose refers to receiving VTS 5 times/week for 20 minutes each; VTS during connected speech
Device: vibro-tactile stimulation (VTS)
High dose refers to receiving VTS 7 times/week for 20 minutes each; non-task-specific, constant stimulation during non-speech
Device: vibro-tactile stimulation (VTS)
High dose refers to receiving VTS 7 times/week for 20 minutes each; VTS during connected speech
Device: vibro-tactile stimulation (VTS)
To apply vibro-tactile stimulation, participants will use a wearable device. It contains two vibratory motors (Precision MicrodrivesTM, Model 307 - 100) that are low-voltage (\~1V), non-invasive and will be located approximately above the lateral portions of the thyroid cartilage. For this protocol, they vibrate at frequencies between 40 - 100 Hz (i.e., 100 times per second
Change in perceived speech effort (PSE)
Speaker will assess effort themselves and assign an score (range: 0-10 with a score of '10' indicating most severe effort)
Time frame: 24 months
Change in smoothed cepstral peak prominence (CPPS)
CPPS provides a measure of the strength of the fundamental frequency within background aperiodicity (physical unit is dB)
Time frame: 24 months
Change in speech quality vector (SQV) (%)
A derived measure designed to understand if a participant's voice symptom improvement occurs across objective (CPPS) and subjective measures of speech (PSE). It is based on the relative change between two time points
Time frame: 24 months
Start is estimated for Aug 2026; primary completion for Aug 2026, 0 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.